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ABSTRACT
INTERACTIONS BETWEEN POLYMER NANOPARTICLES AND
BLOOD PLASMA APPLIED TO DRUG DELIVERY SYSTEMS
by
Mark Stephen Bannon
Targeted nanoparticle drug delivery has the potential to replace current forms of cancer
therapy with previously unparalleled efficiency. Upon introduction into the human body,
nanoparticles exhibit a substantial increase in diameter due to a biomolecular corona
formation caused by interactions between blood plasma proteins and the nanoparticles.
These interactions must be analyzed and understood for targeted delivery to reach its
potential in both feasibility and efficiency.
To study the formation of the protein corona, polystyrene nanoparticles were
incubated in vitro in goat blood plasma for 10-minute intervals, diluted to different degrees
and then measured to obtain the hydrodynamic diameter of said particles. This was done
using Nanoparticle Tracking Analysis (NTA) with the Malvern Nanosight NS300’s more
reliable fluorescent capabilities as opposed to the more commonly used Dynamic Light
Scattering Particle Size Analysis (DLS).
The results of this experiment showed that the size of the nanoparticles being
incubated in blood plasma increases as the solutions become more dilute. These results
were then plotted and characterized by linear regression in order to distinguish between the
hard and soft coronas. The experiment also proved that NTA is a more reliable method for
measuring nanoparticles in blood plasma than the commonly used DLS. These findings
have major implications towards targeted nanoparticle drug delivery and will ultimately
contribute to further research in the subject.
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CHAPTER 1
INTRODUCTION

1.1 Objective
This dissertation’s objective is to quantify the interactions between drug delivery particles
and the biological milieu in which they are working in, in this case blood plasma. For the
dilution experiment used, nanoparticles were incubated in different goat blood plasma
solutions and then diluted with saline. Said plasma was diluted incrementally for each
iteration. Analysis of incubated particle size was done using the Malvern Nanosight
NS300, based upon a comparison of results attained using both nanoparticle tracking
analysis of the Malvern Nanosight NS300 and dynamic light scattering of the Malvern
Zetasizer Nano ZS. The results of said dilution experiment were plotted against the
logarithm of the percentage of plasma in each dilution and regressed linearly using Minitab.
Statistical analysis was then completed on both the plotted data and the linearly regressed
equations to determine the statistical significance of said data.

1.2 Background Information
Nanoparticle drug delivery systems provide a straight-lined method of delivering necessary
therapy to parts of the body that require it. This technology has the potential to replace
harmful techniques, such as systemic chemotherapy, to treat cancer patients, as it would
provide a less harmful and more effective cancer treatment than current techniques can
offer. An example of a nanoparticle used for drug delivery within the human body can be
found in Figure 1.1.
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Figure 1.1 Drug Delivery Nanoparticle Diagram

The blue shell of the nanoparticle represents the actual material comprising the
nanoparticle, in the specific case described in this paper it would be a polymer such as
Polystyrene or PLGA. Other options for this material for drug delivery use include gold or
lipid nanoparticles. The green circle within the nanoparticle represents the encapsulated
drug meant to be delivered to specific targeted areas within the body. Finally, the orange
arrows represent targeting ligands on the surface of the nanoparticles. These ligands can
locate and bond to parts of the body in need of the encapsulated drug, such as tumors. This
binding allows for the nanoparticle to release its encapsulated drug to the intended parts of
the body, completing the drug delivery.
Despite the untapped potential of these systems, there are issues standing between
the design and implementation of nanoparticle drug delivery. One of these issues is the
interactions that occur between nanoparticles and the blood of the patient receiving therapy.
Upon incubation, these nanoparticles demonstrate an affinity to certain compounds that are
present in the blood plasma, specifically plasma proteins. This affinity results in a coating
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of these blood plasma compounds surrounding the nanoparticles, which can cause either a
simple size increase or a large aggregation of particles moving through the body [13].
Upon a nanoparticle’s entrance into the bloodstream, one will observe an increase
in the particle’s hydrodynamic diameter. As the nanoparticle encounters proteins located
in the blood plasma, attractions form between the nanoparticle’s surface and the proteins,
causing the proteins to bind onto the nanoparticle. Unfortunately, these coronas are
extremely complex, resulting from possible interactions with the thousands of different
proteins at differing concentrations present in the blood. In turn, the protein corona of
nanoparticles can differ from patient to patient, incubation to incubation within the same
patient and even from nanoparticle to nanoparticle during the same incubation.
The protein corona can be separated into two different phases: the hard corona and
the soft corona. The current model of a protein corona shows that the hard corona is
comprised of proteins that are directly bound to the nanoparticle surface, acting as an outer
shell around the particle itself [13]. The main method of this protein adsorption is entropydriven binding, which occurs upon the release of water molecules from the surface of the
nanoparticle. The second part of the corona, the soft corona, comprises of proteins that
loosely bind to either the nanoparticle’s surface or the hard corona proteins themselves,
creating protein-protein interactions [13]. The overall development of a protein corona onto
a nanoparticle can be demonstrated by Figure 1.2.
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Figure 1.2 Development of a Protein Corona onto a Nanoparticle

Figure 1.2 represents a protein corona formed upon incubation of one of the
nanoparticles described by Figure 1.1. The red and yellow shapes represent different
proteins contributing to the hard and soft corona; however, it is important to remember that
both layers can be made of a mixture of different proteins. Figure 1.2 shows that the orange
targeting ligands are no longer visible on the surface of the particle. The soft protein corona
primarily contributes to the corona’s overall masking effect, which chemically changes the
composition of the particle within its incubated biological milieu. This masking effect
blocks the targeting ligands from locating and binding to locations in the body that require
the drug encapsulated within the nanoparticle [19]. This diagram shows the negative effects
of protein corona, which can lead to the failure of drug delivery systems.
The composition of the protein corona is determined from many variables, which
include (but are not limited to) nanoparticle size, shape, composition, surface charge,
hydrophobicity/hydrophilicity, etc. Another very important variable affecting the size and
composition of the protein corona is the surface chemistry of the nanoparticle. There are
many methods to change a nanoparticle’s surface chemistry, however one of the most
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effective methods is through PEGylation. PEGylation refers to adding polyethylene glycol
chains to the surface of the nanoparticles, which makes the particle much more hydrophilic
and therefore less prone to aggregation and large protein coronas [13].
While the variables previously discussed contribute heavily to the formation of
protein coronas on select nanoparticles, the corona composition during incubation is
governed by a law known as Vroman’s effect. This law states that the most abundant
proteins are adsorbed onto the nanoparticle surface upon initial incubation, however as
time goes on proteins with higher affinity to the nanoparticles will replace the initially
adsorbed proteins [13]. This presents an even bigger issue, as it Vroman’s effect dictates
that the protein corona is changing over time, with new proteins constantly adsorbing onto
and desorbing from the surface of the nanoparticle. However, it does let us know that
proteins such as albumin, fibrinogen, apolipoproteins and certain immunoglobulins
(among the most abundant proteins in the blood plasma) should always be present on the
protein corona in some capacity [19].
While Vroman’s effect is hard enough to predict, the nanoparticles being incubated
in blood plasma will constantly be in motion, which the conducted experiments do not
account for. When nanoparticles are incubated in a dynamic environment, the effect of
Brownian motion must be considered. Brownian motion is based upon random movement
of particles in suspension, which causes the nanoparticle surface adsorption of a plasma
protein to be dependent upon the probability of that specific protein species to encounter
the nanoparticle. By this logic, larger proteins and proteins in high abundance are more
likely to adsorb onto the nanoparticles and become part of the protein corona, as they take
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up a larger volume within the bloodstream and are more likely to collide with the
nanoparticles [13]. Brownian motion will be discussed in greater detail in Chapter 2
The masking effect that accompanies these interactions between the nanoparticles
and blood plasma components ultimately causes drug delivery through these nanoparticle
systems to become a near impossible task. In order to efficiently implement nanoparticle
drug delivery to its full potential, one must first understand the interactions between the
nanoparticles and the plasma components. For this reason, it is extremely important to
understand not only how Vroman’s effect collaborates with Brownian motion, but also how
to control the two laws.
The plasma being used for this experiment is derived from goat blood. While the
eventual drug delivery systems will be applied to human test subjects, goat plasma serves
as an effective and safer substitute. A study done by Morris et al compared human blood
plasma with that of various animals, including goats, by zone electrophoresis.

Figure 1.3 Comparison between Human and Goat Blood Plasma Using Zone Electrophoresis
Source: Morris, Bede, and F. C. Courtice. “The Protein And Lipid Composition Of The Plasma Of Different
Animal Species Determined By Zone Electrophoresis And Chemical Analysis.” Quarterly Journal of
Experimental Physiology and Cognate Medical Sciences, vol. 40, no. 2, 7 Nov. 1955, pp. 127–137.,
doi:10.1113/expphysiol.1955.sp001104.

6

The above graphs display the similarities between goat and human blood plasma.
The large peak on the right indicates the relative amount of the plasma protein albumin in
both types of blood: the results clearly show that goat blood plasma contains more. Goat
blood plasma also contains higher concentrations of gamma globulin and fibrinogen, two
proteins very abundant in human blood plasma. Goat blood plasma also contains beta and
alpha globulin fractions. The major difference comes with the lipid composition. Zone
electrophoresis separated lipids available in human plasma into three distinct categories,
while goat blood plasma’s lipids were only separated into two categories. Despite this
minor difference, Morris confirms that it is acceptable to use goat blood plasma as a
substitute for human blood plasma [16].
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CHAPTER 2
METHOD COMPARISON FOR NANOPARTICLE SIZE MEASUREMENT

2.1 Dynamic Light Scattering
Dynamic light scattering is the most common technique used to size nanoparticles in
suspensions [19]. When in a suspension such as blood plasma, nanoparticle movement
adheres to the laws of Brownian motion, which is used to describe the randomized
movement of microscopic particles in a fluid. This erratic movement is usually a result of
constant bombardment by molecules of the surrounding medium, which in these
experiments is blood plasma [6]. Because these particles are so small, and their randomized
location makes it impossible to predict their locations, it is quite difficult to see, and
therefore size, these particles. DLS transmits waves of light through a suspension with
microscopic particles. The particles will scatter this transmitted light, which allows for their
state of motion to be measured [10].
DLS uses the Stokes-Einstein equation to calculate a particle’s hydrodynamic
diameter. The Stokes-Einstein equation can be shown in Figure 2.1:

Figure 2.1 Stokes-Einstein Equation
Source: Wade Hedegard, Anatomy & Physiology: Fluids and Transport. OpenStax CNX.Jun 27, 2017
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In the above equation, “k” represents Boltzmann’s constant, “T” represents absolute
temperature, and “Ƞ” represents the dynamic viscosity of the suspension. DLS measures
the parameter “D”, which is the translational diffusion coefficient. This parameter
describes the speed of the Brownian motion [6]. Because the other parameters are usually
known, it becomes easy to measure “d(H)”, which represents the hydrodynamic diameter
of particles in suspension. Hydrodynamic refers to “how a particle diffuses within a fluid”.
Because it is impossible to know the exact shape of the particles through DLS, the
hydrodynamic diameter represents the diameter of a sphere that has the same translation
diffusion coefficient as the particle [6].
DLS calculates this hydrodynamic diameter using the measured intensity of light
scattered from particles in suspension. This intensity is then fit to a correlation curve, where
the correctness of fit is determined for the measured data. The correlation curve will always
be used to calculate the perceived hydrodynamic diameters of the particles, however the
accuracy of said curve depends upon the quality of the data measured from a sample [6].
While dynamic light scattering is a useful technique for nanoparticle sizing, it has
a significant drawback that prevents it from being reliable for sizing polymer nanoparticles
in blood plasma. Blood plasma has an innumerable amount of proteins in it, which just as
readily scatter light as the polymer nanoparticles being used in drug delivery solutions. The
problem is that as plasma is introduced into the solution, a large amount of plasma proteins
enters the system, which can create variation in the measurements in two ways. One,
variation in the sizes of particles present in suspension will affect the correlation curve and
produce a less accurate fit of size data. Second, as there becomes a greater concentration
of similarly sized proteins (or other blood plasma constituents) than polymer nanoparticles
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in the solution, then DLS will be measuring the size of those more abundant proteins. This
makes it nearly impossible to measure the size of nanoparticles in solvents mainly
comprised of blood plasma. To understand how these particles behave in the blood stream,
it is important to be able to measure their size in pure blood plasma. While DLS is a more
common and perfected technique for particle sizing, its ambiguity in nanoparticle
selectivity provides a problem in implementation.

2.2 Nanoparticle Tracking Analysis
The idea of nanoparticle tracking analysis is similar to that of dynamic light scattering,
where a laser is sent through a microfluidic device containing a suspension of particles in
blood plasma. It also uses the Stokes-Einstein equation to calculate hydrodynamic
diameters of particles. As opposed to DLS, NTA analyzes the individual sizes of
nanoparticles by measuring the translational diffusion coefficient of each nanoparticle in
suspension. The mode size of particles present in the suspension will then be reported,
according to the concentration of the particles in suspension per milliliter [14].
As discussed in the previous section, DLS has trouble differentiating between the
proteins found in blood plasma and the nanoparticles in suspension. NTA has the
convenience of customized lasers and fluorescent filters, which send out specific
wavelengths of light that can excite the fluorescently tagged nanoparticles. The fluorescent
light from the fluorescently tagged particles has a higher wavelength than the laser used to
excite them; for example, if a 488-nanometer laser was sent into the suspension, the
fluorescent light from the fluorescent yellow-green tagged nanoparticles would be over
500 nanometers. On the contrary, particles that aren’t fluorescently tagged, such as proteins
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found in blood plasma, will only scatter light at the same wavelength of the laser. If a 500
nm fluorescent filter is being used, the scattered light at 488 nm will be blocked and only
the fluorescent light from the nanoparticles will be analyzed [14].
Essentially, the fluorescent capabilities of NTA allow users to measure only their
targeted particles in suspensions while blocking the scattered light from unwanted
particles. This unwanted scattered light is also referred to as “noise”. This enhanced
measuring selectivity makes NTA a theoretically superior method of sizing drug delivery
nanoparticles in suspensions containing blood plasma. In addition, the fluorescent
capabilities of NTA could theoretically allow a user to determine the size of particles in
undiluted blood plasma, which is not possible in DLS. The theoretical capabilities of NTA
make it a more suitable technique for evaluating polymer drug delivery nanoparticles in
blood plasma than DLS [14].

2.3 Methods and Materials
Whole goat blood with Alsevers solution was purchased from Lampire Biological
Laboratories. Alsevers solution served as the anticoagulant in the blood and refers to an
isotonic salt solution. The specific blood purchased comprised of 50% Alsevers solution
and 50% whole goat blood. Whole goat blood with Alsevers solution was chosen to match
the same type of blood used in earlier experiments so comparisons could be made between
the two samples. The blood was centrifuged for one hour, after which the resulting
supernatant was removed and then centrifuged for another hour. This process was repeated
three total times until the blood cells were removed and blood plasma was attained.
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Plasma accounts for about 55% of whole blood, and therefore after centrifugation
the resultant solution is about 35.50% plasma and 64.50% isotonic salt solution, making
the highest attainable percentage of plasma in dilution, which is represented by dilution 0,
35.50% [4] [6] [20] [21] [24]. Because of the heavy dilution, the mixture of goat plasma
and Alsevers will be referred to as “plasma solution”.
The polystyrene particles were incubated in various amounts of plasma for 10
separate dilutions. Each dilution contains 10 microliters of polystyrene nanoparticle
solution (made of 100 microliters of stock yellow-green fluorescently-tagged polystyrene
nanoparticle solution diluted with 900 microliters of saline solution) in 1000 microliters of
a saline solution and plasma mixture. Dilution 0 contained 1000 microliters of plasma
solution, with the amount of plasma in solution incrementally halved until dilution 9, the
final dilution, contained 1.95 microliters of plasma solution and 998.05 microliters of saline
solution. Table 2.1 summarizes each dilution, describing the amount of plasma and isotonic
salt solution (Alsevers and saline) in each solvent dilution. The percentage of plasma
solution in each dilution can be found in the second column of Table 2.1.
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Table 2.1 Amount of Plasma in Numbered Dilutions

Dilution 0

Volume of
Incubation
Solution
(µL)
1000.00

Percentage of
Plasma in
Final Dilution
(µL)
35.50%

Volume of
Plasma in
Final Dilution
(µL)
355.00

Volume of
Saline in
Final Dilution
(µL)
645.00

Dilution 1

500.00

17.75%

177.50

822.50

Dilution 2

250.00

8.88%

88.75

911.25

Dilution 3

125.00

4.44%

44.38

955.62

Dilution 4

62.50

2.22%

22.19

977.81

Dilution 5

31.25

1.11%

11.09

988.91

Dilution 6

15.63

0.55%

5.55

994.45

Dilution 7

7.81

0.28%

2.77

997.23

Dilution 8

3.91

0.14%

1.39

998.61

Dilution 9

1.95

0.07%

0.69

999.31

Dilution #

Each particle suspension was vortexed for 10 seconds, and then placed in a water
bath at 37°C for 10 minutes, which simulated environmental conditions of the human body.
After this 10 minute incubation period, saline was added to the solution until it had a
volume of 1000 microliters, or 1 milliliter. The saline solution was previously heated to
37°C for the same amount of time as the particle suspension to ensure that a constant
temperature was maintained. For this specific experiment, dilutions 6 through 9 as well as
nanoparticles measured in pure saline solution were prepared and analyzed using DLS and
NTA. For the solution of pure saline, 10 microliters of polystyrene nanoparticle solution
were incubated in 1000 microliters of saline solution at 37°C for 10 minutes.
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First, for DLS, the solution was loaded into a disposable plastic cuvette by means
of transfer pipette. This plastic cuvette was then loaded into a Malvern Zetasizer Nano ZS,
of which a schematic can be found in Figure A.1. A standard operating procedure was
created in which 3 sets of 12 measurements were taken to analyze the size of any particles
in solution, each measurement lasting 5 seconds. For each set, the results of the 12
measurements were averaged together to determine the most commonly recurring peak
sizes, or modes, of the hydrodynamic diameter data analyzed. For each dilution, the peak
with the highest intensity, or the most commonly recorded peak size, was taken and
averaged together to retrieve one overall dilution peak size. The full summary of analyzed
data from the DLS can be found in Table A.1.
In the case of NTA, the respective dilutions were loaded into the Nanosight NS300
and pumped continuously through the microfluidic viewing device. The syringe pump was
set to a flow rate of 100, which is measured using an arbitrary unit interpreted by the
Nanosight NS300. This flow rate resulted in particles crossing the viewing area in five to
ten seconds, the recommended time for particle analysis by NTA. The inner chamber of
the Nanosight was then set to 37°C to maintain solution temperature throughout the
experiments. This temperature mimics the temperature within the human body, allowing
for the system to simulate the environment that the nanoparticles would experience in the
body with as much accuracy as possible. The solution was analyzed using a 488-nanometer
laser and a 500-nanometer fluorescent filter. A schematic of the Nanosight NS300 can be
found in Figure C.1
Sizing was completed by recording 10 one-minute videos of the particles in
solution, and then allowing the Nanosight NS300 to analyze said videos. This protocol was
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repeated three times for each of the ten diliutions until there were over 20 reliable video
analyses. To be considered reliable, each solution had to have a concentration of at least
1 × 108 particles per mL and not exceed minor vibration within the sample run time. If the
sample was deemed acceptable, the mode hydrodynamic diameter of every fluorescently
tagged particle was then calculated by the Stokes-Einstein equation (see Figure 2.1). The
generalized particle size of each particle in solution was then determined by the mode of
the calculated diameters from the Nanosight NS300’s analyzing capabilities.
Finally, referring to Figure 2.1, the Stokes-Einstein equation takes the dynamic
viscosity of the solvent being used into effect. Because each dilution’s viscosity is different,
kinematic viscosity measurements had to be individually performed on each of the ten
dilutions using a glass kinematic viscometer and then converted into dynamic viscosity.
This can theoretically be done by multiplying the kinematic viscosity of a solution by the
solution’s density, which was measured for each dilution used. The viscosity of each
separate dilution was measured and taken into account to achieve accurate results, which
is further discussed in Appendix B.

2.4 Results
The experiments explained in Section 2.3 resulted in measured hydrodynamic diameters of
nanoparticles after incubation in various plasma dilution. This data is summarized in Tables
A.1 and C.1 and is also plotted in Figure 2.2.
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Figure 2.2 Plotted Hydrodynamic Diameters of Polystyrene Nanoparticles After
Incubation in Various Dilutions of Blood Plasma and Saline Solution

Figure 2.2 shows the vast differences between the measurements taken by the two
systems, where experiments were performed on dilutions 6 through 9. The asterisks next
to the data points indicate that data quality used to create said points on the graph was too
poor for an accurate result using the correlation function of DLS. Each plotted point
represents the average of the mode hydrodynamic particle diameters for each individual
measurement in DLS and NTA.
Firstly, the standard error of each measurement using DLS is much greater than that
of the NTA NS300. This is made visually apparent by the graph; however, as seen in Tables
A.1 and C.1, the error produced by the Nanosight NS300 is in between 1 and 4 nanometers,
while the error produced by the DLS is in between 9 and 17 nanometers. The low standard
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error boasted by the Nanosight NS300 makes it a superior instrument, and as these
experiments deal with extremely small size difference, it would create more reliant results
than DLS.
In order to accurately assess the results of these two methods, a comparison of the
development of the results must be done. Figures 2.3 and 2.4 shows a comparison between
the hydrodynamic diameters visually plotted by both DLS and NTA, respectively.

Figure 2.3 Intensity Plotted Against Size Data Calculated by DLS in the Malvern Zetasizer
Nano ZS Assessed According to the Goodness of Fit Shown by the Expert Advice Tab for
Saline, Dilution 0
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218

Figure 2.4 Nanoparticle Concentration Plotted Against Size Data Calculated by NTA in
the Nanosight NS300 for Saline, Dilution 0

Figure 2.3 shows the results of an individual DLS measurement characterized by
the intensity of scattered light from particles in suspension plotted against their sizes on a
semi log plot. Figure 2.4 shows the results of an individual NTA measurement
characterized by the concentration of particles in suspension, also plotted against their sizes
on a semi log plot. Both results are for particles incubated in pure saline.
Clearly, according to the expert advice tab for DLS’s measurement of particles in
pure saline, the “data meets quality criteria”, meaning that it is accurate enough to calculate
the size of the nanoparticles in suspension correctly. Therefore, the 207.90 nanometer size
of the particles can be considered an accurate measurement. This is also comparable to the
size of nanoparticles measured by the Nanosight NS300, which is 218.00 nm. Because
18

these two methods are analyzing size in different ways (NTA by number and DLS by
intensity), they are not expected to produce exactly similar hydrodynamic diameters.
Based on these results, both methods measure accurate hydrodynamic diameters of
nanoparticles with limited error in a suspension of pure saline; however, the peak width of
the Nanosight NS300’s data is clearly much smaller than the peak width of the Malvern
Nanosight NS300’s data. This peak width is another testament to the accuracy of the
Nanosight NS300 in saline size measurements, as the thinner peak represents less variable
size measurements in each device. This trend of the Nanosight NS300’s thinner peaks will
continue throughout the dilutions.
Figures 2.5 and 2.6 represent the result of nanoparticle incubation in Dilution 8,
which contains a small amount of plasma.
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Figure 2.5 Intensity Plotted Against Size Data Calculated by DLS in the Malvern Zetasizer
Nano ZS Assessed According to the Goodness of Fit Shown by the Expert Advice Tab for
Plasma, Dilution 8

20

Figure 2.6 Nanoparticle Concentration Plotted Against Size Data Calculated by NTA in
the Nanosight NS300 for Plasma, Dilution 8

Once again, Figure 2.5 and 2.6 represent the results of two individual runs of
Dilution 8 on the Nanosight NS300 and the Malvern Zetasizer. Unlike Figure 2.3, the
Expert Advice reports the data quality as “too poor for cumulant analysis”, meaning that
the correlation function used to size the data had too much error to accurately measure the
hydrodynamic diameters using DLS. This is because there was too much variation in
scattered light within the data, which one can only assume to be resulting from the addition
of plasma and its inherent plasma proteins. Because the data quality is considered poor, the
measured hydrodynamic diameter of 250.60 cannot be considered an accurate
measurement. At the same time two other peaks are present in Figure 2.5, at 6.38 and 20.11
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nm. The addition of plasma could lead one to assume that these two peaks represent
different components within the plasma, most likely plasma proteins.
The peak of the NTA is still extremely defined, with no other peaks even coming
close to the high concentration of the peak representing 278 nm. There is obviously a much
larger difference between the results from DLS and NTA, and the poor quality of the DLS
correlation fit leads users to consider the NTA’s measurement of 278 nm to be more
accurate. Once again, the Nanosight NS300’s plotted data has a much narrower peak than
the Zetasizer ZS’s. Obviously, as plasma is added to the incubating solution, there is a
decrease in accuracy and reliability in results from DLS. Figures 2.7 and 2.8 show DLS
and NTA data, respectively, for Dilution 6.

Figure 2.7 Intensity Plotted Against Size Data Calculated by DLS in the Malvern Zetasizer
Nano ZS Assessed According to the Goodness of Fit Shown by the Expert Advice Tab for
Plasma, Dilution 6
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Figure 2.8 Nanoparticle Concentration Plotted Against Size Data calculated by NTA in
the Nanosight NS 300 for Plasma, Dilution 6

Once again, Figure 2.7 and 2.8 represent the results of two individual runs of
Dilution 6 on the Nanosight NS300 and the Malvern Zetasizer. The Expert Advice reports
the data quality as “too poor for cumulant analysis” for Dilution 6, meaning that the
correlation function used to size the data had too much error to accurately measure the
hydrodynamic diameters using DLS. Because the data quality is considered poor, the
measured hydrodynamic diameter of 232.60 nm cannot be considered an accurate
measurement. It is also important to note that this size is smaller than that calculated by
DLS in Dilution 8, while the size for NTA is conversely increasing as the solutions become
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less dilute. It is safe to assume that the fit of the correlation function in the DLS
measurement becomes poorer as more plasma is present in incubation and that this trend
does not accurately reflect the real trend followed by incubated nanoparticles. The other
peaks from Figure 2.5 are present in Figure 2.7 as well, and have increased in intensity,
with the peak of 20.11 nm becoming comparable to the peak of 232.60. This also advocates
the lower quality of Dilution 6’s data as opposed to Dilution 8’s in the Zetasizer ZS.
The peak of the NTA is still extremely defined, with no other peaks even coming
close to the high concentration of that representing the 293 nm particles. Once again,
conversely to DLS data, the size of the nanoparticles is increasing as the dilutions become
less dilute. There is obviously a much larger difference between the results from DLS and
NTA, and the poor quality of the DLS correlation fit leads users to consider the NTA size
of 293 nm more accurate. The Nanosight NS300’s plotted data still has a much narrower
peak than the Zetasizer ZS’s. As the solutions become less dilute, there is a decrease in
accuracy and reliability in results from DLS.
Obviously, one of these methods is providing flawed measurements of nanoparticle
sizes in blood plasma. In theoretical terms, one would be inclined to claim that DLS
presents flawed measurements as the percentage of plasma in dilution increases, which is
supported by the poor quality of data used in the correlation function of the Zetasizer ZS’s
measurements. Figure 2.9 provides an explanation for this poor data quality.
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Figure 2.9 Diagram of Nanoparticles in Blood Plasma

Figure 2.9 represents a suspension of fluorescently tagged nanoparticles in blood
plasma, much like the ones used in these experiments. The red, translucent background
represents the blood plasma while the abundant, small red and yellow circular shapes
represent plasma proteins within the plasma. The bright yellow fluorescently tagged
polystyrene nanoparticles can still be clearly seen, however it would be impossible to
measure the size of these nanoparticles due to the plasma proteins surrounding them. DLS
shares this problem. There are thousands of different proteins in blood plasma, meaning
that even if the different scattered light did not affect the quality of the data, the scattered
light from the plasma proteins would be measured due to the higher concentration of
proteins in solution. This can be compared to the fluorescent capabilities of the Nanosight
NS300, which can be seen in Figure 2.10.
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Figure 2.10 Fluorescently Tagged Nanoparticles in Plasma Viewed through Fluorescent
Filter

Figure 2.8 shows scattered light from fluorescently tagged nanoparticles viewed on
the Nanosight NS300. Using the proper combination of lasers and fluorescent filters, the
scattered light from the plasma proteins is not analyzed by the NS300, and only the
fluorescent light from the fluorescently tagged nanoparticles is analyzed. Figure 2.10 still
shows the outline of the protein corona formed onto the fluorescently tagged nanoparticles.
Even though the light scattered by the protein corona is blocked by the filter, it’s existence
still affects how the nanoparticles move through the suspension and will therefore affect
the measured translational diffusion coefficients of the nanoparticles.
The poor data quality displayed in the results is theoretically explained by the
abundance of plasma proteins in each solution, which in turn affects the Zetasizer ZS’s
correlation function, making the results less accurate. The clear and concise peaks shown
by the measurements of the Nanosight NS300 can be explained by the use of fluorescent
filters, which block all scattered light other than that from the fluorescently tagged
polystyrene nanoparticles. After looking at both the theoretical usages and the measured
data sets, it is clear that NTA through the Nanosight NS300 is more reliable than DLS
through the Malvern Zetasizer Nano ZS for measuring the size of nanoparticles in blood
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plasma. For that reason, the Nanosight NS300 was used for the dilution experiments to size
polymer nanoparticles in blood plasma.
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CHAPTER 3
PLASMA DILUTION EXPERIMENT

3.1 Methods and Materials
As discussed in Chapter 2, the Nanosight NS300 provides the most accurate size
measurements of nanoparticles in blood plasma, and therefore was the primary instrument
used to do so. Both the solution preparation and the Nanosight NS300 operation were
previously described in Section 2.2, and no changes were made to either of those
procedures to carry out the experiments discussed in this section. In addition to measuring
dilutions 6 through 9, the remaining dilutions were also prepared, measured and analyzed
using the Nanosight NS300.
The dilution experiments were carried out on two separate batches of goat blood
plasma, both ordered from Lampire Biological Laboratories. One of the experiment sets
was carried out in the Spring of 2016 by Dr. Kathleen McEnnis while the second set was
carried out in the Summer of 2018 by Mark Bannon. The same exact stock solution of
polystyrene nanoparticles was used for each of the sets of experiments. The goat blood
plasma batch used in the set of 2018 experiments will be referred to as “Plasma 2”, while
the batch used in 2016 will be referred to as “Plasma 1”. To properly analyze the effects of
the plasma dilutions and eventual protein corona formation on the incubated polystyrene
particles, a control of measured polystyrene particles in pure saline solution was deemed
necessary.
A control solution was created for each of the ten dilutions. Just like the plasma
dilutions, 10 microliters of polystyrene nanoparticles were incubated using the same exact
procedure, however the specific volume of plasma solution used for incubation was
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replaced with the same volume of saline solution. After the ten-minute incubation period,
additional saline (preheated to 37°C) was added to the incubated solution, and the resulting
suspension was measured by the Nanosight NS300. The Nanosight NS300’s laser,
temperature and recording settings were identical to those described in Section 2.2.

3.2 Measured Size of Nanoparticles in Blood Plasma
The measured hydrodynamic diameter of nanoparticles after incubation in the various
dilutions for each batch of plasma and pure saline can be summarized in Tables C.1 through
C.5. The information is visually summarized below in Figure 3.1.

Figure 3.1 Plotted Hydrodynamic Diameter of Polystyrene Nanoparticles After
Incubation in Various Dilutions of Blood Plasma and Saline Solution
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In addition to graphing the measured hydrodynamic diameter of the nanoparticles,
fitted equations were created through linear regression. While these fitted lines appear as
linear equations, they are logarithmic equations. For the exact fitted equations and
associated R2 values, see Table C.6. Like Figure 2.6, each data point represents the average
size data calculated from three runs of in between seven and 10 measurements taken with
each dilution.
Firstly, it is clear that similar trends exist between each batch of plasma. As the
solutions become less dilute, the measured size of the nanoparticles in solution increases.
Next, some overlap can be seen between data points in the two separate batches. This
suggests that different batches of plasma can produce the same sized nanoparticle protein
corona for the same dilution, however statistical analysis would be warranted in order to
be able to conclude this. Statistical analysis should also be done on each dilution in each
batch of plasma in order to conclude the statistical difference between measured
nanoparticle hydrodynamic diameters developed in each respective dilution. Finally, both
the developed slope and the overall similarities in the measured sizes of nanoparticles in
pure saline solutions lead to the assumption that, in pure saline, the particles’ hydrodynamic
diameters are statistically similar across each dilution. Once again, this warrants statistical
analysis to confirm, which will be further discussed in Chapter 4.
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CHAPTER 4
STATISTICAL ANALYSIS OF POLYSTYRENE NANOPARTICLE SIZE DATA

4.1 Analysis of Variance
Statistical significance can be determined between two or more groups of raw data through
a single factor analysis of variance (ANOVA). This method assesses the amount of
variance both within and between group means, and then compares the two values together.
From these variances, several parameters are created for analysis. The sum of squares
between groups (SSB) represents the variation of group means from the total mean, while
the mean of squares between groups (MSB) is the SSB divided by the degrees of freedom
between groups. Vice versa, the sum of squares within groups (SSW) represents the sum
of squared deviations of the group means and individual observations. Like the MSB, the
mean of squares within groups (MSW) is equal to the SSW divided by the degrees of
freedom [11].
Next, the ratio of the MSB and MSW is determined, which compares between
group variance and within group variance, generally referred to as F. There is also a precalculated expected value of F, which is called the critical F value. If the F value is greater
than the critical F value, then there are differences between group means that cannot be
accounted for by error or chance. Conversely, if the F value is smaller than the critical F
value then the two sets of data are considered statistically similar, meaning that any
differences in the datasets can be explained by error [11]. Single Factor ANOVA was
performed on the two batches of data in Microsoft Excel. First, ANOVA tests were
preformed on each dilution for pure saline and both batches of plasma to determine
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statistical significance between dilutions. Next, an ANOVA test was performed on each
batch of plasma to determine the statistical significance between batches.

4.2 ANOVA Test on Dilutions of Pure Saline
The single factor ANOVA test on hydrodynamic diameters of polystyrene particles
measured in pure saline is summarized in Table 4.1.
Table 4.1 Single Factor ANOVA Summary of Hydrodynamic Diameters of Nanoparticles
Incubated in 10 Incremental Dilutions of Saline
SUMMARY
Groups
Dilution 0
Dilution 1
Dilution 2
Dilution 3
Dilution 4
Dilution 5
Dilution 6
Dilution 7
Dilution 8
Dilution 9

Count
25
30
25
30
30
25
30
27
28
30

ANOVA
Source of Variation
Between Groups
Within Groups
Total

SS
df
1365.48 9
34217.49 267
35582.97 276

Sum
5111.20
6091.10
5067.40
6173.80
6000.40
5196.40
6014.60
5521.70
5684.30
6057.50

Average
204.45
203.04
202.70
205.79
200.01
207.86
200.49
204.51
203.01
201.92

Variance
532.06
57.57
72.64
64.39
46.53
152.26
33.99
359.30
76.77
28.39

MS
151.72
128.16

F
1.18

P-value
0.31

F crit
1.92

The calculated F value was 1.18, while the critical F value was 1.92. As the
calculated F value is less than the critical F value, the measured hydrodynamic diameters
of nanoparticles measured in pure saline are found to be statistically similar to each other.
This not only proves that the size of the nanoparticle can indeed be confirmed constant
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across each dilution in saline, but it also proves that a significant nanoparticle protein
corona is being measured in plasma.
The statistical similarity of the measured hydrodynamic diameters proves that the
variation in procedure between each dilution does not cause a size increase in
nanoparticles. The only difference between the saline and plasma measurements is the fact
that plasma is being added to the incubation solution. Because the dilution procedure does
not cause fluctuation in size, the interactions between plasma and the nanoparticles are
causing an increase in size. In other words, the Nanosight NS300 is measuring
nanoparticles with a sizeable protein corona on them when incubated in plasma.

4.3 ANOVA Test Across Dilutions of Plasma Batches
The single factor ANOVA test on hydrodynamic diameters of polystyrene particles
measured in Plasma Batch 1 is summarized in Table 4.2.
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Table 4.2 Single Factor ANOVA Summary of Hydrodynamic Diameters of Nanoparticles
Incubated in 7 Incremental Dilutions of Plasma 1

Unfortunately, raw data was only available for dilutions 0-6 for Plasma 1, the data
for which is shown in Table 4.6. Here, the F-value of 12.69 is much larger than the critical
F value of 2.14, showing that the measured hydrodynamic diameters of polystyrene
nanoparticles incubated in Plasma 1 are statistically different across each dilution. In other
words, there is a different sized protein corona developed onto the incubated nanoparticles
for each dilution of Plasma 1.
The single factor ANOVA test on hydrodynamic diameters of polystyrene particles
measured in Plasma Batch 2 is summarized in Table 4.3.
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Table 4.3 Single Factor ANOVA Summary of Hydrodynamic Diameters of Nanoparticles
Incubated in 10 Incremental Dilutions of Plasma 2

Once again, the F-value of 50.54 is much larger than the critical F value of 1.92,
showing that the measured hydrodynamic diameters of polystyrene nanoparticles
incubated in Plasma 2 are also statistically different across each dilution. Because of the
statistical difference displayed across dilutions 0-10 in Tables 4.2 and 4.3, the trends shown
in Figure 3.1 can be confirmed. As each nanoparticle suspension becomes less dilute with
respect to plasma, the measured hydrodynamic diameter of nanoparticles increases.
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4.4 ANOVA Test Across Separate Plasma Batches
The single factor ANOVA test on the average hydrodynamic diameters of polystyrene
particles in each dilution measured in Plasma Batch 1 and Plasma Batch 2 is summarized
in Table 4.4.
Table 4.4 Single Factor ANOVA Summary of Measured Hydrodynamic Diameters of
Nanoparticles Incubated in Plasma 1 and Plasma 2

The F-value of 2.26 is obviously smaller than the critical F-value of 4.41, meaning
that the measured hydrodynamic diameters of nanoparticles in their respective dilutions are
statistically similar across each batch of plasma. This confirms the visual similarities
between each set of data in plasma shown in Figure 3.1, and that two batches of plasma
from the same species will produce similar sized protein coronas. The statistical analysis
of the hydrodynamic diameters of nanoparticles in each dilution was useful, however it
would be more useful to be able to characterize data specifically describing the size of the
protein corona.
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CHAPTER 5
AVERAGE PROTEIN CORONA THICKNESS ANALYSIS

5.1 Average Thickness of Developed Protein Coronas
According to the definition of the protein corona discussed in Chapter 1, the protein
corona can be thought of as a shell around the nanoparticle in solution. Because the
Nanosight NS300 assumes that all measured particles are perfectly spherical, that same
assumption can be applied to a particle’s protein corona. It is important to note that it is
not guaranteed that every nanoparticle and its resulting corona will be perfectly spherical
in shape. By subtracting the true measured size of the nanoparticles in saline for each
dilution from the hydrodynamic diameter of the particle and protein corona and then
dividing the resultant number in half, the actual thickness of the protein corona was able
to be determined. This information is summarized in Tables C.7 and C.8 for both batches
of blood plasma used.
The thickness ranges in between 20 and 50 nanometers, with standard error that is
once again very low, ranging from 1 to 5 nm. While these thicknesses seem negligible in
terms of size, they become very significant when taking the size of the nanoparticles being
used into account. In terms of percent change, incubation of nanoparticles in blood plasma
was found to increase the overall nanoparticle diameter from anywhere between 20% and
50% of its original size. This change is substantial and based upon the trends seen in Figure
3.1, when a nanoparticle is incubated in undiluted blood plasma in a human body, this
change could increase even more. The information in Tables C.7 and C.8 is visually
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summarized in Figure 5.1

Figure 5.1 Average Thickness of Protein Coronas After Incubation in Various Dilutions
of Blood Plasma and Saline Solution for Plasma 1 and Plasma 2

Like Figure 3.1, there is a clearly positive trend portrayed by the data. As the plasma
solutions become less dilute, the resultant protein corona becomes thicker. This makes
sense, as the protein corona thickness is directly related to the overall hydrodynamic
diameter of the nanoparticles in incubation. This figure just provides a more streamlined
way of looking at the data. More detailed information about the logarithmic relationships
derived by linear regression can be found in Table 5.1.
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Table 5.1 Fitted Equations Developed from the Linear Regression of the Data Plotted in
Figure 5.1

Once again, overlap can be seen between thickness data points in the two separate
batches of plasma. This suggests that different batches of plasma can produce protein
corona with similar thickness. Based upon the statistical analysis done on the
hydrodynamic diameters of the incubated nanoparticles between batches of plasma, it is
assumed that this conclusion is accurate, however more statistical analysis would be
warranted. Statistical analysis should also be done on each dilution in each batch of plasma
in order to conclude the difference between protein corona thickness developed in each
respective dilution of each batch of plasma. Finally, statistical analysis should be
completed on the linear regression equations in Table 5.1 to determine their statistical
significance.

5.2 ANOVA Tests on Average Protein Corona Thickness
The ANOVA test on the average protein corona thickness of nanoparticles incubated in
each respective dilution of Plasma 1 is summarized in Table 5.2.
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Table 5.2 Single Factor ANOVA Summary of Average Protein Corona Thickness of
Nanoparticles Incubated in 7 Incremental Dilutions of Plasma 1

Once again, raw data was only available for dilutions 0-6 for Plasma 1, the data for
which is shown in Table C.3. Here, the F-value of 12.94 is much larger than the critical F
value of 2.14, showing that average protein corona thickness of polystyrene nanoparticles
incubated in Plasma 1 are statistically different across each dilution. In other words, there
is a different sized protein corona developed onto the incubated nanoparticles for each
dilution of Plasma 1. Because the average protein corona thickness is directly related to the
measured hydrodynamic size of nanoparticles in suspension, this result was expected.
The ANOVA test on the average protein corona thickness of nanoparticles
incubated in each respective dilution of Plasma 2 is summarized in Table 5.3.
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Table 5.3 Single Factor ANOVA Summary of Average Protein Corona Thickness of
Nanoparticles Incubated in 10 Incremental Dilutions of Plasma 2

The F-value of 50.12 is much larger than the critical F value of 1.92, showing that
the average protein corona thickness of polystyrene nanoparticles incubated in Plasma 2
are also statistically different across each dilution. Because of the statistical difference
displayed across dilutions in Tables 5.2 and 5.3, the trends shown in Figure 5.1 can be
confirmed. As each nanoparticle suspension becomes less dilute with respect to plasma,
the average thickness of the protein corona developed onto nanoparticles increases.
The ANOVA test on average protein corona thickness of nanoparticles incubated
in dilutions across each batch of plasma used is summarized in Table 5.4

41

Table 5.4 Single Factor ANOVA Summary of Average Protein Corona Thickness of
Nanoparticles Incubated in Plasma 1 and Plasma 2

The F-value of 2.24 is obviously smaller than the critical F-value of 4.4, meaning
that the average protein corona thickness of nanoparticles incubated in their respective
dilutions are statistically similar across each batch of plasma. This confirms the visual
similarities between each set of data in plasma shown in Figure 3.1, and that two batches
of plasma from the same species will produce similar sized overall protein coronas. Being
able to compare overall protein coronas is useful, however, as discussed in Chapter 1,
protein corona is characterized by both the hard and soft corona. Therefore, it is important
to be able to differentiate between these two components in these measurements.

5.3 Statistical Analysis of Average Protein Corona Thickness Regression
Table 5.1 displays the equations of the fitted lines plotted on Figure 5.1, comparing the
average protein corona thickness to the logarithm of the percentage of plasma present in
each dilution. The two equations look visually similar on Figure 5.1 and appear to have
comparable slopes and intercepts. Based upon the definition of a protein corona, it was
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determined that these linear equations could be used to characterize the size of the hard
and soft protein coronas within each batch of plasma.
It was determined that the slope of the linear equation determines the effect of the
soft corona on the overall average protein corona thickness, while the constant of the linear
equation determines the effect of the hard corona on the overall average protein corona
thickness. Recalling the definition of protein corona, the hard corona is comprised of one
layer of proteins that are directly bound to the surface of the nanoparticle. Therefore, it can
be assumed that compared to the thickness of the overall protein corona, which is around
50 nanometers, the small thickness of the hard corona will stay fairly constant across the
protein coronas developed in each dilution. In an equation that determines the overall
thickness, it should be represented by the unchanging constant. The slope of the equation
determines the change in the overall thickness of the protein corona, and as the solutions
become less dilute the thickness increases. Therefore, it can be assumed that the
nanoparticles incubated in the less dilute solutions have the same sized hard corona but
have larger soft coronas. Therefore, as the slope accounts for variation between dilutions,
it therefore represents the size of the soft corona.
In order to analyze the difference between the hard and soft corona across batches
of plasma, statistical analysis needed to be performed on the two linear regression
equations. Statistical analysis of slopes and constants produced through linear regression
can be completed through hypothesis testing. For both the slopes and the constants, the two
data sets were separated by a categorical variable, which identified which set of plasma the
data was being used for incubation.
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For the developed slopes, a fitted regression was developed for each set of data
while taking an interaction effect into account. Interaction effects display the effects of
factors on each dependent measure, or the size/thickness of the particle/protein corona,
showing that the impact of a factor depends on the level of another factor [12]. In this case,
the interaction effect is the product of the log of the percentage of plasma in solution and
the categorical variable, “Plasma Batch”, with “A” representing Plasma 2 and “B’
representing Plasma 1. This procedure provides two linear fits with which the developed
coefficients (or slopes) could be assessed. Figure 5.2 shows an example of the results of a
hypothesis test on two sets of developed slopes and constants [18].

Figure 5.2 Minitab Results from a Coefficient Comparison Between Two Independently
Developed Coefficients Using a Hypothesis Test.
Source: Ogee, Agnes, et al. “How to Compare Regression Slopes.” The Minitab Blog, Minitab, 13 Jan. 2016,
blog.minitab.com/blog/adventures-in-statistics-2/how-to-compare-regression-lines-between-differentmodels.

A couple of things should be seen in a coefficient table such as above. When
considering the significance of the slopes, the cell of value is the intersection between
“Input*Condition”, which is the interaction effect, and P-Value. The hypothesis test starts
with the hypothesis that the two developed slopes of the linear regressions are equal, which
would be supported by a P-value of greater than the confidence interval at which this
analysis was ran, which for all intents and purposes will be 0.05 [12]. In Figure 5.2, the P-
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Value of the interaction term is 0, which is less than 0.05, and therefore the null hypothesis
can be rejected, and the two slopes can be considered statistically significant [18].
When considering the significance of the constants, the cell of value is the
intersection between “Condition” and P-Value. The hypothesis test starts with the
hypothesis that the two developed constants of the linear regressions are equal, which
would be supported by a P-value greater than the confidence interval at which this analysis
was ran, which for all intents and purposes will be 0.05. In Figure 5.2, the P-Value of the
interaction term is 0, which is less than 0.05, and therefore the null hypothesis can be
rejected, and the two coefficients can be considered statistically significant. These
principles will now be provided to the previously discussed data [18]. Table 5.5 displays
the statistical analysis of the linearly regressed equations fit to the average protein corona
thickness of nanoparticles incubated in Plasma 1 and Plasma 2.

Table 5.5 Regression Analysis of Fitted Equations Developed from the Data Plotted in

Obviously, the P-Value associated with the interaction effect (Plasma
Concentration*Plasma Batch B) is larger than the confidence interval of 0.05, with a value
of 0.332. This means that the null hypothesis cannot be rejected, and that there is no
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statistical significance between the two slopes produced by the linear regression of the
average protein corona thickness plotted against the logarithm of the percentage of plasma
present in each dilution. Because there is no statistical significance between the two slopes
produced by linear regression of the average protein corona thickness for each plasma
batch, it can be concluded that the soft corona has the same effect on the overall protein
corona for different batches of plasma from the same species. In other words, each batch
of plasma should have similarly sized soft protein coronas.
The P-Value associated with the Plasma Batch value is smaller than the confidence
interval of 0.05, with a value of 0.003. This means that the null hypothesis can be rejected,
and that there is a statistical significance between the two constants produced by the linear
regression of the average protein corona thickness plotted against the logarithm of the
percentage of plasma present in each dilution. Because there is a statistical significance
between the two constants produced by linear regression of the average protein corona
thickness for each plasma batch, it can be concluded that the hard corona has a different
effect on the overall protein corona for different batches of plasma from the same species.
In other words, each batch of plasma should have different sized hard protein coronas.
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CHAPTER 6
FUTURE WORK

6.1 Dilution Experiment Expansion
The dilution experiment was an excellent springboard towards understanding protein
corona composition, however much more work needs to be done to confirm some of the
discovered trends. In order to determine the validity of future use of the Nanosight NS300,
experiments will need to be done in which nanoparticles are incubated in undiluted blood
plasma. This will allow for a more accurate simulation of the interactions between blood
plasma proteins and nanoparticle drug delivery solutions. As the goal of these experiments
is to simulate flow of nanoparticle drug systems within the human body, the ability to
measure the hydrodynamic diameter of nanoparticles in undiluted plasma is crucial to
future implementation.
Different types of blood plasma must be tested in order to confirm the existence of
the claimed trends across different species. Because human blood plasma is a biohazard
and requires special engineering controls to safely use, it would be wise to test the claim
on another animal. Figure 6.1 shows a comparison of the results of zone electrophoresis
between ox (bovine) plasma and human plasma.
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Figure 6.1 Comparison Between Human and Ox Blood Plasma Using Zone
Electrophoresis.
Source: Source: Morris, Bede, and F. C. Courtice. “The Protein And Lipid Composition Of The Plasma Of
Different Animal Species Determined By Zone Electrophoresis And Chemical Analysis.” Quarterly Journal
of Experimental Physiology and Cognate Medical Sciences, vol. 40, no. 2, 7 Nov. 1955, pp. 127–137.,
doi:10.1113/expphysiol.1955.sp001104.

Like goat blood plasma, bovine plasma is quite similar to human blood plasma.
Both plasma types contain significant amounts of fibrinogen, gamma, beta and alpha
globulins and albumin. Zone electrophoresis also migrated the lipids contained in bovine
plasma into two distinct areas, despite human lipids being migrated into three. However,
both lipid migrations contained a zone localized around the albumin and beta-globulin
protein areas [16]. Bovine plasma is safer to use than human blood, and its use will be a
greater step forward in either confirming or denying some of the trends seen in goat plasma
across different types of plasma. While the goal still remains to be able to control protein
corona in human plasma, use of all other plasma types still acts as an intermediary to
performing experiments using human plasma.
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Different nanoparticles with different surface chemistries must be used in future
experiments. The important of surface charge and various physical characteristics of
nanoparticle systems in protein corona formation was discussed in Chapter 1, and it
remains an important task to understand the roles of these traits in protein corona
development. A commonly used polymer in nanoparticle drug delivery systems is
poly(lactic-co-glycolic acid), also known as PLGA. Another popular substance used is gold
nanoparticles, which are often used in cancer remediation because of the inherent stability
to assembly and malleable surface properties [9]. Another option is changing the surface
chemistry of the PLGA nanoparticles by using polyethylene glycol, or PEG, which
theoretically masks nanoparticles from proteins in blood plasma [1]. Not only will varying
the surface chemistry and types of nanoparticle systems provide more information upon
nanoparticle and plasma protein interactions, but it could lead towards information on the
most efficient and useful nanoparticle system. PEGylated particles have already been
synthesized using 1K, 5K, 10K and 30K PEG, and future experiments will be done on
those particles in order to determine their influence on the development of the protein
corona.

6.2 Determining Protein Corona Composition
To prove the theories discussed from the results of the hypothesis testing, one would have
to be able to physically distinguish between the hard and soft corona. In Microfluidic
Examination of the ‘Hard’ Biomolecular Corona Formed on Engineered Particles in
Different Biological Milieu, Weiss discusses a technique for washing nanoparticles after
incubation. This washing, theoretically, would remove the soft corona from the
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nanoparticles, as it is weakly bound to the particle. However, the proteins that make up the
hard corona should be able to retain their bonds to the particle. By this logic, one would be
able to measure the size of only the particle and the hard corona. The sizes of these washed
particles could then be compared from dilution to dilution, and if the theory holds up, would
prove that the size of each nanoparticle and hard corona would be constant regardless of
the amount of blood plasma each nanoparticle is incubated in [23]. Therefore, any
hydrodynamic diameter variation seen in Figure 3.1 or thickness variation seen in Figure
5.1 would be a direct result in a change in the size of the soft protein corona.
Weiss also discusses the possible determination of the composition of the hard
corona after the washing step through gel electrophoresis and mass spectrometry. Gel
electrophoresis would allow the proteins present on the hard corona to be separated by
atomic mass. Mass spectrometry would be able to determine the relative amounts of each
protein in the hard protein corona [23]. These experiments are extremely important for
multiple reasons.
First, understanding the proteins that make up the protein corona could allow
different measures to be taken to avoid the binding of those proteins, such as changing
nanoparticle surface chemistry. Knowing the relative amounts of the proteins present in the
protein corona will give more information on how the protein corona is formed, and a better
inherent understanding of the clashing between Vroman’s Effect and Brownian Motion.
Finally, knowing the composition of individual protein coronas would give information on
the binding affinities of individual proteins, which would help future design of drug
delivery nanoparticles and even assist in perfecting the quantification of the effective
binding coefficient of plasma. This information could be vital to the implementation of
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nanoparticle systems as drug delivery solutions, and therefore experiments to determine
protein corona composition are vital for future research.

6.3 Binding Affinity
A successive project resulting from this work would be to calculate the binding affinity of
blood plasma to nanoparticles. According to experiments done by Zhang et al., the binding
affinity is calculated using calorimetry data from nanoparticle incubation in blood plasma,
attained using Isothermal Titration Calorimetry. Binding affinities in the literature are
calculated for individual protein solutions and nanoparticles incubated within them,
however the goal is to be able to calculate said binding affinities for overall batches of
plasma containing many different proteins and then comparing the affinities for similarities
[25].
The binding affinity can be calculated from the Gibb’s Free Energy, which can be
calculated from the enthalpy and entropy measured through calorimetry data. The equation
for the binding affinity is ∆G = RT × ln(𝑘𝐴 ), Where ∆G is the Gibb’s Free Energy, R is
the universal gas constant, T is the absolute temperature and kA is the binding affinity of
the solvent. By comparing the binding affinities of batches of plasma with those from
individual protein solutions it is believed that the composition of the protein corona will be
able to be determined, or at least easier to characterize. A goal is also to measure these
binding affinities onto different types of nanoparticles, such as the newly developed
PEGylated PLGA particles or even gold nanoparticles [25].
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CHAPTER 7
CONCLUSION

While the experiments and resultant analysis discussed above give updated and useful
information about protein corona, it is clear that many more experiments will have to be
carried out before nanoparticle drug delivery systems are efficient. The results of the
dilution experiment generated some interesting claims and trends, all of which will be
referred to and implemented in further work. That being said, there is definitely a future
for nanoparticle drug delivery in pharmaceutical practice.
Firstly, NTA is a more reliable method of measuring the hydrodynamic diameter
of nanoparticles in solutions containing blood plasma. It was made clear that measurements
from DLS were unreliable and theoretically inaccurate even at dilutions containing a small
amount of goat blood plasma. The measurements using the Nanosight NS300 appeared
accurate up to the 35.5% blood plasma solution that has been tested so far, however the
machine’s fluorescent capabilities should allow for the hydrodynamic diameter of
nanoparticles to be measured in undiluted blood plasma, which is crucial, as that is what
nanoparticles will be in when implemented in the body.
The dilution experiment proved the existence of protein corona around polystyrene
nanoparticles upon incubation in blood plasma. The statistical similarity between the
hydrodynamic diameters of polystyrene nanoparticles across all ten “dilutions” of pure
saline proved that neither the saline nor the dilution preparation should have any effect on
the size of the nanoparticles, and all size changes are a result of the interactions between
the nanoparticles and the blood plasma. On the other hand, the statistical significance of
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the measured diameters of polystyrene nanoparticles across all ten dilutions of plasma in
each batch prove that each dilution produces a different sized protein corona.
After careful statistical analysis using single factor ANOVA, it was determined that
the both the measured hydrodynamic diameters of and average protein corona thickness
surrounding each polystyrene nanoparticle were considered statistically similar for both
batches of goat plasma used. Hypothesis testing on the slopes and constants generated by
regression showed that while the slopes were statistically similar, the developed constants
were not. This can be translated in terms of the soft and hard corona, saying that the size
of the soft corona will stay generally constant and the hard corona will change between
batches of blood plasma from the same species, specifically goat plasma. In order to
actually prove this claim, more experiments will have to be done in goat plasma, as a
sample size of two batches simply is not enough to make any accurate assumptions.
Finally, future work must be done in order to ensure the massive potential of
nanoparticle drug delivery is reached. More experiments must be done using blood plasma
from different species, different types of nanoparticles, different nanoparticle surface
charges, and finally using human blood plasma. The composition of developed protein
coronas can be determined from gel electrophoresis and mass spectrometry, and therefore
experiments should be designed to determine said composition in order to understand the
best way to inhibit nanoparticle interactions with specific proteins within the plasma.
Finally, calorimetry data of the development of a protein corona upon incubation of
nanoparticles should be collected in order to calculate binding affinities of plasma onto
specific nanoparticle surfaces.
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APPENDIX A
Dynamic Light Scattering

A.1 Malvern Zetasizer Nano ZS

Figure A.1 Schematic of Malvern Zetasizer Nano ZS

The above schematic shows the operation of the Malvern Zetasizer Nano ZS. A cuvette
containing a suspension (in this case blood plasma dilutions with polystyrene
nanoparticles) is placed into the machine and the lid is closed. A laser then shines light
through the samples, which will then be scattered by any particles that come into contact
with it. This scattered light is reflected towards a detector, which will send a signal to the
computer. The result of this system is the measured hydrodynamic diameter of the
nanoparticle as a function of the intensity of scattered light sent to the detector.
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A.2 Dilution Experiment
Raw data from DLS is in the form of the correlation function, which the software fits to
produce the size distribution as the intensity of scattered light plotted against the measured
hydrodynamic diameters of the particles in suspension. The fit to the correlation function
developed in order to create the size distribution is described by the “Expert Advice” Tab
in the Zetasizer’s user interface. This tab describes the goodness of fit of the size data, and
where the sample quality was good enough to produce an accurate function. The DLS
results for each of the separate runs are displayed in the following figures.

Figure A.2 DLS Results from Polystyrene Nanoparticles Incubated in Saline, Run #1
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Figure A.3 Description of Data Quality for Saline, Run #1

Figure A.4 DLS Results from Polystyrene Nanoparticles Incubated in Saline, Run #2
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Figure A.5 Description of Data Quality for Saline, Run #2

Figure A.6 DLS Results from Polystyrene Nanoparticles Incubated in Saline, Run #3
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Figure A.7 Description of Data Quality for Saline, Run #3

Figure A.8 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 9, Run #1
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Figure A.9 Description of Data Quality for Dilution 9, Run #1

Figure A.10 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 9, Run
#2
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Figure A.11 Description of Data Quality for Dilution 9, Run #2

Figure A.12 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 9, Run #3
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Figure A.13 Description of Data Quality for Dilution 9, Run #3

Figure A.14 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 8, Run #1
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Figure A.15 Description of Data Quality for Dilution 8, Run #1

Figure A.16 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 8, Run #2
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Figure A.17 Description of Data Quality for Dilution 8, Run #2

Figure A.18 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 8, Run #3
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Figure A.19 Description of Data Quality for Dilution 8, Run #3

Figure A.20 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 7, Run #1
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Figure A.21 Description of Data Quality for Dilution 7, Run #1

Figure A.22 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 7, Run #2
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Figure A.23 Description of Data Quality for Dilution 7, Run #2

Figure A.24 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 7, Run #3
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Figure A.25 Description of Data Quality for Dilution 7, Run #3

Figure A.26 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 6, Run #1
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Figure A.27 Description of Data Quality for Dilution 6, Run #1

Figure A.28 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 6, Run #2
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Figure A.29 Description of Data Quality for Dilution 6, Run #2

Figure A.30 DLS Results from Polystyrene Nanoparticles Incubated in Dilution 6, Run #3
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Figure A.31 Description of Data Quality for Dilution 6, Run #3

The individual data shown in Figures A.2 through A.31 is summarized in Table
A.1. Averages for each dilution were calculated by averaging the most frequently measured
nanoparticle hydrodynamic diameter within each dilution, and then displayed in the fifth
column of the table.
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Table A.1 Hydrodynamic Diameters of Polystyrene Particles Incubated in Plasma 2
Dilutions Using DLS
Dilution

Run
1

6

2

3

1

7

2

3

1

8

2

3

1
9

Saline

2
3
1
2
3

Peak Size
(nm)
173.00
16.24
5483.00
209.90
11.97
28.03
232.60
20.42
195.90
20.23
255.90
14.87
236.10
14.38
247.30
11.30
22.10
250.60
20.11
6.38
240.60
24.27
9.50
244.70
14.92
6.95
290.40
253.20
207.90
233.30
237.70

% Intensity
79.30
19.70
1.00
78.30
12.00
9.70
79.60
20.40
88.00
12.00
88.50
11.50
88.20
11.80
91.00
4.80
4.20
90.20
6.80
1.80
89.30
5.60
3.90
94.40
4.90
0.70
100.00
100.00
100.00
100.00
100.00
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Average
of Mode

Count

Standard
Deviation

Standard
Error

205.17

42

8.89

1.37

229.30

42

9.39

1.45

246.17

36

9.50

1.58

262.77

36

9.91

1.65

226.30

36

13.13

2.19

APPENDIX B
Viscometry

Due to the required accuracy needed for the Nanosight NS300 to correctly distinguish the
size of the particles to the nanometer, a Fisherbrand Traceable thermometer was used to
closely monitor and ensure that the temperature was retained at 37°C. Fourteen milliliters
of each dilution were prepared and heated to 37°C by means of a water bath. These samples
were then loaded into a glass Ubbelohde capillary viscometer. Ten separate measurements
were taken at 37°C for each dilution. In order to attain the dynamic viscosity of each
dilution, the measured kinematic viscosity in
kg

m2
s

was multiplied by the density of the
kg

dilution’s density, in m3, in order to get the dynamic viscosity, in m×s. The results attained
from this method are summarized in Table B.1.
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Table B.1 Kinematic Viscosity of Dilutions of Goat Blood Plasma and Saline Converted
to Dynamic Viscosity Using Density

Dilution #

Measured
Kinematic
Viscosity
𝐦𝟐

(

𝐬

)

Density
𝐤𝐠
(𝐦𝟑 )

Converted
Dynamic
Viscosity
𝐤𝐠
(𝐦×𝐬)

Standard
Error
𝐤𝐠
(𝐦×𝐬)

Dilution 0

0.970

1

0.970

0.003

Dilution 1

0.841

1

0.841

0.006

Dilution 2

0.769

1

0.769

0.003

Dilution 3

0.747

1

0.747

0.005

Dilution 4

0.732

1

0.732

0.003

Dilution 5

0.727

1

0.727

0.004

Dilution 6

0.722

1

0.722

0.001

Dilution 7

0.736

1

0.736

0.002

Dilution 8

0.730

1

0.730

0.001

Dilution 9

0.738

1

0.738

0.003

To measure the density of each dilution, a 2mL Eppendorf tube was massed and
then loaded with either 500, 750, or 1000 μL of one of the ten dilutions. The overall mass
of the tube and the solution would then be taken, and the mass of the tube would be
subtracted from the overall mass in order to calculate the final mass of the dilution. The
mass of the solution would then be divided by the overall volume in order to achieve the
kg

density in final units of m3 . This process was repeated for each dilution, and the standard
deviation was then taken between the three volumes. The error between the three
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measurements was determined small enough to conclude that the amount of volume used
to measure did not affect the overall density measurement, and therefore all 30 individual
measured densities for each dilution were averaged. There was clearly an error in the values
of the measured dilutions, and the averaged values are included in the Table B.2.

Table B.2 Actual Density Values of Each Dilution
Dilution

Average Density
𝐤𝐠
(𝐦𝟑 )

Standard Deviation

Standard Error
𝐤𝐠
(𝐦𝟑 )

Dilution 0

0.990

0.004

0.001

Dilution 1

0.978

0.010

0.003

Dilution 2

0.947

0.023

0.008

Dilution 3

0.973

0.007

0.002

Dilution 4

0.966

0.016

0.005

Dilution 5

0.969

0.004

0.001

Dilution 6

0.977

0.020

0.007

Dilution 7

0.972

0.003

0.001

Dilution 8

0.967

0.009

0.003

Dilution 9

0.971

0.025

0.008

The density of saline solution is 1.0046

kg
m3

, and human blood plasma can be

kg

approximated to around 1.0025 m3 [7] [21]. By this logic, the density of any dilution of
blood plasma and saline solution needs to be in between those two values. All the calculated
kg

average densities were consistently under 1 m3, which is obviously not the correct density
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of any of the dilutions. This error could have occurred in the actual measurement, although
the consistency and low standard error in measurements says otherwise. The most likely
source of error comes from clotting factors within the plasma, such as fibrinogen,
aggregating within the plasma over time, and affecting the density of the plasma upon
measurement, as these measurements were done on Plasma 1 well after the earlier
experiments were completed.
kg

Because the densities of the two solutions are so close to 1 m3 , substituting the
measured kinematic viscosity as the dynamic viscosity would produce less error than using
the measured densities of the blood plasma to convert between the two. As a matter of fact,
the error within the Nanosight NS300’s individual measurements are larger than the error
provided with this substitution. Therefore, in order to correctly measure the hydrodynamic
viscosities of the particles in each dilution, the kinematic viscosity was considered equal
to the dynamic viscosity of each dilution.
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APPENDIX C
NANOPARTICLE TRACKING ANALYSIS

C.1 Malvern Nanosight NS300

Figure C.1 Schematic of Malvern Nanosight NS300

Figure C.1 displays a schematic of the Nanosight NS300. First, a sample is loaded into a
syringe, which is then connected to a tube that feeds into the Nanosight. The sample is then
pumped into a microfluidic device sitting on top of a laser module. An objective attached
to a camera hangs over this viewing plate and has the ability to record the light scattered
by the particles as the laser sends light through the sample. The data captured by the camera
is then analyzed, during which each beam of scattered light is analyzed by the Nanosight
NS300 to calculate the measured hydrodynamic diameter of each particle. A “mode size”
is then reported, which represents the most frequently measured size of the particles in
solution.

76

C.2 Dilution Experiment
The measurement procedure was repeated with two sets of blood plasma and pure saline,
and the data is summarized for each run of each dilution in Tables C.1 – C.5.

Table C.1 Hydrodynamic Diameters of Polystyrene Nanoparticles Incubated in Plasma 2
Dilution #

Percent of
Plasma
in Solution

Average
Mode
(nm)

Count

Standard
Deviation
(nm)

Standard
Error (nm)

Dilution 0

100

297.98

22

9.63

2.05

Dilution 1

50

303.11

24

7.70

1.57

Dilution 2

25

269.54

24

58.17

11.87

Dilution 3

12.5

283.33

27

11.95

2.30

Dilution 4

6.25

275.32

20

8.57

1.92

Dilution 5

3.125

277.64

30

11.12

2.03

Dilution 6

1.5625

270.91

26

7.35

1.44

Dilution 7

0.78125

263.12

21

4.64

1.01

Dilution 8

0.390625

262.55

23

4.81

1.00

Dilution 9

0.1953125

269.57

26

8.63

1.69
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Table C.2 Raw Data Used to Calculate the Hydrodynamic Diameters of Polystyrene
Nanoparticles Incubated in Plasma 2
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Table C.3 Hydrodynamic Diameters of Polystyrene Particles Incubated in Plasma 1
Dilution #

Percent of
Plasma
in Solution

Average
Mode
(nm)

Count

Standard
Deviation
(nm)

Standard
Error
(nm)

Dilution 0

100

294.73

42

21.78

3.36

Dilution 1

50

286.74

42

32.33

4.99

Dilution 2

25

284.34

35

21.41

3.62

Dilution 3

12.5

272.04

28

8.28

1.56

Dilution 4

6.25

272.23

25

12.76

2.55

Dilution 5

3.125

263.35

28

15.92

3.01

Dilution 6

1.5625

266.35

49

11.30

1.61

Dilution 7

0.78125

253.75

30

7.18

1.31

Dilution 8

0.390625

253.32

29

7.71

4.32

Dilution 9

0.1953125

251.74

28

9.83

1.86
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Table C.4 Hydrodynamic Diameters of Polystyrene Particles Incubated in Saline Solution

Dilution 0

Percent of
“Plasma”
in Solution
100

Average
Mode
(nm)
204.45

25

Standard
Deviation
(nm)
24.34

Standard
Error
(nm)
4.87

Dilution 1

50

203.04

30

7.59

1.39

Dilution 2

25

202.69

25

8.52

1.70

Dilution 3

12.5

205.79

30

8.02

1.47

Dilution 4

6.25

200.01

30

6.82

1.25

Dilution 5

3.125

207.86

25

12.34

2.47

Dilution 6

1.5625

200.49

30

5.83

1.06

Dilution 7

0.78125

204.51

27

18.96

3.65

Dilution 8

0.390625

203.01

28

8.76

1.66

Dilution 9

0.1953125

201.92

30

5.33

0.97

Dilution #

Count
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Table C.5 Raw Data Used to Calculate Hydrodynamic Diameters of Polystyrene Particles
Incubated in Saline Solution

Table C.6 Fitted Equations Relating Hydrodynamic Diameter with Percentage of Plasma
in Dilution
Data Set

R2

Equation

Plasma 2

Y = 14.21 × log10 (X) + 276.41

0.79

Plasma 1

Y = 14.89 × log10 (X) + 265.82

0.90

Saline

Y = 0.58 × log10 (X) + 202.35

0.06

Tables C.7 and C.8 display the measured protein corona thickness in each dilution.
The calculations to produce these values are discussed in length in Chapter 4.
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Table C.7 Average Protein Corona Thickness of Polystyrene Particles Incubated in Plasma
1
Dilution

Average
Corona
Thickness

Standard
Deviation

Standard
Error

Percent
Change

Standard
Error

Dilution 0

45.14

25.12

3.02

22.08%

0.07

Dilution 1

41.85

33.12

4.21

20.61%

0.08

Dilution 2

40.82

23.04

2.97

20.14%

0.06

Dilution 3

33.13

11.53

1.51

16.10%

0.04

Dilution 4

36.11

15.07

2.03

18.05%

0.04

Dilution 5

28.03

17.32

2.38

13.49%

0.07

Dilution 6

32.93

16.73

1.88

16.43%

0.04

Dilution 7

24.62

9.250

1.23

12.04%

0.08

Dilution 8

25.15

20.46

2.71

12.39%

0.04

Dilution 9

23.99

13.17

1.90

11.77%

0.04
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Table C.8 Average Protein Corona Thickness of Polystyrene Particles Incubated in Plasma
2

Dilution 0

Average
Corona
Thickness
48.24

Dilution 1

53.41

3.94

0.8

26.31%

0.03

Dilution 2

47.13

5.07

1.06

23.25%

0.04

42.76

6.14

1.18

20.78%

0.04

42.45

4.43

0.99

21.22%

0.03

39.38

5.74

1.05

18.95%

0.05

42.23

3.86

0.76

21.06%

0.03

33.08

2.39

0.52

16.18%

0.07

34.99

2.5

0.52

17.24%

0.04

35.19

4.31

0.85

17.43%

0.03

Dilution

Dilution 3
Dilution 4
Dilution 5
Dilution 6
Dilution 7
Dilution 8
Dilution 9

Standard
Deviation

Standard
Error

Percent
Change

Standard
Error

4.86

1.04

23.60%

0.09
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